Maunuksela EL, Korpela R, Olkkola KT. 1988a. Double-blind, multiple – dose comparison of buprenorphine and morphine in postoperative pain of children. Br J Anesth, 60:48–55. Maunuksela EL, Korpela R, Olkkola KT. 1988b. Comparison of buprenorphine with morphine in the treatment of postoperative pain of children. Anesth Analg, 67:233–9. McCormack K, 1999. Signal transduction in neuropathic pain, with special emphasis on the analgesic role of opioids – Part II: Moving basic science towards a new pharmacology. Pain Rev, 6:99–131. McQuay HJ, Moore RA, Bullingham RES. 1986. Buprenorphine kinetics. In: Advances in pain research and therapy. Vol 8. New York: Raven Pr. p 271–8. McQuay HJ, Moore RA. 1995. Buprenorphine kinetics in humans. In: Cowan A, Lewis JW (eds). Buprenorphine combating drug abuse with a unique opioid. New York: Wiley-Liss. p 137–47. Mercadante S, Arcuri E. 2004. Opioids and renal function. J Pain, 5:2–19. Moore RA, Sear JW, McQuay HJ, et al. 1994. Renal failure: effects on morphine and buprenorphine kinetics in man. Pain, (Suppl 2):S398. Muriel C; the Opioid Study Group of the Spanish Pain Society. 2004. Assessment of the transdermal buprenorphine patch in patients with cancer pain. Rev Soc Esp Dolor, 11(Suppl 5):41–8. Nasar MA, McLeavy MA, Knox J. 1986. An open study of sub-lingual buprenorphine in the treatment of chronic pain in the elderly. Curr Med Res Opin, 10:251. Ohtani M, Kotaki H, Sawada Y, et al. 1995. Comparative analysis of buprenorphine- and norbuprenorphine-induced analgesic effects based on pharmacokinetic-pharmacodynamic modeling. J Pharmacol Exp Ther, 272:505–10. Olkkola KT, Leijala MA, Maunuksela EL. 1995. Paediatric ventilatory effects of morphine and buprenorphine revisited. Paediatr Anaesth, 5:303–5. Poulain P, Denier W, Seremet W et al. 2005. Efficacy and safety of transdermal buprenorphine 70µg/h in patients suffering from severe chronic cancer pain. A randomized, placebo-controlled, double-blind multicentre study [abstract, poster]. Presented at the Deutsche Gesellschaft zum Studium des Schmerzes (German Society for the Study of Pain). 6–10 October, Bremen, Germany. Radbruch L, Sabatowski R, Petzke F, et al. 2001. Transdermal fentanyl for the management of cancer pain: a survey of 1005 patients. Palliat Med, 15:309–21. Radbruch L. 2003. Buprenorphine TDS: use in daily practice, benefits for patients. Int J Clin Pract Suppl, 133:19–22. Robinson SE. 2002. Buprenorphine: an analgesic with an expanding role in the treatment of opioid addiction. CNS Drug Rev, 8:377–90. Rodriguez MJ; the Opioid Study Group of the Spanish Pain Society, 2004. Transdermal buprenorphine in neuropathic pain. Rev Soc Esp Dolor, (Suppl 5):11–21. Safety of pain management with transdermal buprenorphine Schriek P. 2004. Treatment of cancer-related pain with transdermal buprenorphine: a report of three cases. Support Care Cancer, 12: 882–4. Sittl R, Griessinger N, Likar R. 2003. Analgesic efficacy and tolerability of transdermal buprenorphine in patients with inadequately controlled chronic pain related to cancer and other disorders: A multicenter, randomized, double-blind, placebo-controlled trial. Clin Ther, 25: 150–68. Sittl R, Likar R, Nautrup BP. 2005. Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and non-cancer pain: results of a prospective cohort study. Clin Ther, 27:225–37. Sittl R, Nuitjen M, Nautrup BP. 2005. Changes in the prescribed daily doses of transdermal fentanyl and transdermal buprenorphine during treatment of patients with cancer and non-cancer pain in Germany result of a retrospective cohort study. Clin Ther, 27:1022–31. Summerfield RJ, Allen MC, Moore RA. 1985. Buprenorphine in end stage renal failure. Anaesthesia, 40:914. Tegeder I, Lotsch J, Geisslinger G. 1999. Therapy with opioids in liver or renal failure. Schmerz, 13:183–95. Tyers MB, 1980. A classification of opiate receptors that mediate antinociception in animals. Br J Pharmacol, 68:503–12. Tzschentke T. 2002. Behavioral pharmacology of buprenorphine, with a focus on preclinical models of reward and addiction. Psycho- pharmacology, 161:1–16. Umehara K, Shinokawa Y, Miyamoto G. 2002. Inhibition of human drug metabolizing cytochrome P450 by buprenorphine. Biol Pharm Bull, 25:682–5. Van Loveren H, Gianotten N, Hendriksen CFM, et al. 1994. Assessment of immunotoxicity of buprenorphine. Lab Anim, 28:355–63. Walsh SL, Preston KL, Stitzer ML, et al. 1994. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther, 55:569–80. Walsh SL, Eissenberg T. 2003. The clinical pharmacology of buprenorphine: extrapolating from the laboratory to the clinic. Drug Alcohol Depend, 70(Suppl 2):S13–27. Womer DE, De Lapp NW, Shannon HE. 1997. Intrathecal pertussis toxin produces hyperalgesia and allodynia in mice. Pain, 70:223–8. [WHO] World Health Organisation. 1996. Cancer pain relief: with a guide to opioid availability. 2nd Ed. WHO, Geneva. Zaki PA, Keith DE, Brine GA et al. 2000. Ligand induced changes in surface µ-opioid receptor number: relationship to G protein activation? J Pharmacol Exp Ther, 292:1127–34. Zhang W, Ramamoorthy Y, Tyndale RF, et al. 2003. Interaction of buprenorphine and its metabolite norbuprenorphine with cytochromes p450 in vitro. Drug Metab Dispos, 31:768–72. Zech DF, Grond S, Lynch J. 1995. Validation of World Health Organization Guidelines for cancer pain relief: a 10-year prospective study. Pain, 63:65–76. Therapeutics and Clinical Risk Management 2006:2(1) 125